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Abstract
Background: Epithelial-mesenchymal transition (EMT) played an important role in the progression of hepatocellular
carcinoma (HCC) after insufficient radiofrequency ablation (RFA). However, whether sorafenib could be used to suppress
the EMT of HCC after insufficient RFA and further prevent the progression of residual HCC remains poorly unknown.
Methods: Insufficient RFA was simulated using a water bath (47 °C 5, 10, 15, 20 and 25 min gradually). MTT assay and
transwell assay were used to evaluate the effects of sorafenib on viability, migration and invasion of HepG2 and
SMMC7721 cells after insufficient RFA in vitro. After insufficient RFA, the molecular changes in HCC cells with the
treatment of sorafeinb were evaluated using western blot and ELISAs. An ectopic nude mice model was used to
evaluate the effect of sorafenib on the growth of HepG2 cells in vivo after insufficient RFA.
Results: HepG2 and SMMC7721 cells after insufficient RFA (named as HepG2-H and SMMC7721-H) exhibited enhanced
viability, migration and invasion in vitro. Sorafenib inhibited the enhanced viability, migration and invasion of HepG2
and SMMC7721 cells after insufficient RFA. Molecular changes of EMT were observed in HepG2-H and SMMC7721-H
cells. Sorafenib inhibited the EMT of HepG2-H and SMMC7721-H cells. HepG2-H cells also exhibited larger tumor size in
vivo. Higher expression of PCNA, Ki67, N-cadherin, MMP-2 and MMP-9, was also observed in HepG2-H tumors.
Sorafenib blocked the enhanced growth of HepG2 cells in vivo after insufficient RFA.
Conclusions: Sorafenib inhibited the EMT of HCC cells after insufficient RFA, and may be used to prevent the
progression of HCC after RFA.
Keywords: Hepatocellular carcinoma, Insufficient radiofrequency ablation, Epithelial-mesenchymal transition, Sorafenib
Background
Hepatocellular carcinoma (HCC) is the fifth most com-
mon tumor worldwide and is the third most common
cause of cancer-related death [1]. Radiofrequency ablation
(RFA) is emerging as an effective local treatment for cura-
tive intent in patients with cirrhosis and HCC smaller
than 3 cm in diameter [2]. However, the major problem
with RFA is its difficulty in achieving complete tumor
destruction [3], and several cases of rapid and aggressive
recurrence of HCC after RFA have been reported [4–6].
Several mechanisms have been proposed to explain
the phenomenon of progression of HCC after insuffi-
cient RFA [7–12]. Epithelial-mesenchymal transition
(EMT) is a complex process, involving dissolution of
cell-cell junctions and loss of apical-basolateral polarity,
resulting in transition of epithelial cells into migratory
mesenchymal cells with invasive properties [13]. Yoshida
et al. reported that sublethal heat treatment skews HCC
cells toward EMT and transforms them to a progenitor-
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like, highly proliferative cellular phenotype in vitro and
in vivo, which driven significantly by p46Shc-ERK1/2,
and suboptimal RFA accelerates HCC growth and spread
by transiently inducing an EMT-like, more aggressive
cellular phenotype [12]. Our previous study established a
model simulating insufficient RFA in vitro and showed
that insufficient RFA could directly promote the inva-
siveness and metastasis of HCC cells and the EMT of
HCC cells through Akt and ERK signaling pathways
[11]. However, there are no researches about exploring
effectual approaches to prevent the progression of HCC
after insufficient RFA.
Sorafenib is the first and only molecular targeted ther-
apy approved for use in HCC by the U.S. Food and Drug
Administration in 2007. Currently, sorafenib is used as a
standard treatment for patients with advanced HCC.
Sorafenib inhibited the EMT induced by transforming
growth factor β1 in mouse hepatocytes and hepatocyte
growth factor in HCC [14, 15]. Sorafenib ameliorated
bleomycin-induced pulmonary fibrosis through inhibit-
ing EMT and fibroblast [16], and inhibited EMT in
human lung epithelial cells [17]. Sorafenib was also used
to suppress postsurgical recurrence and metastasis of
HCC in an orthotopic mouse model, indicating that
sorafenib had a potential application in early-stage HCC
patients who have undergone hepatectomy with curative
intention [18]. Apart from its successful application in
patients with advanced, unresectable HCC, however, the
use of sorafenib in patients with early-stage HCC is
largely untested; this is especially true for patients who
are considered as appropriate candidates for curative
intervention. Whether sorafenib could be used to sup-
press the EMT of HCC after insufficient RFA and fur-
ther prevent the progression of residual HCC remains
poorly unknown.
In the present study, we established a simulated model
to understand the recurrence of aggressive HCC after
insufficient RFA. We investigated the effects of sorafenib
on cell growth, migration and invasion of HCC cell lines
(HepG2 and SMMC7721) after insufficient RFA in vitro.
Furthermore, we analyzed the influences of sorafenib on
changes of epithelial and mesenchymal markers, and
Akt and ERK1/2 signaling pathways involved in the
process in HCC cells after insufficient RFA. We also per-
formed in vivo experiments to study the effect of sorafe-
nib on the growth of HCC cells after insufficient RFA in
a BALB/c nu/nu mice model.
Methods
Ethics statement
All animal experiments were approved by Animal Care
Committee of Capital Medical University and per-
formed in accordance with the institutional guideline.
All sections of this report adhere to the ARRIVE Guidelines
for reporting animal research [19]. A completed ARRIVE
guidelines checklist is included in Additional file 1.
Reagents
Sorafenib was kindly provided by Bayer Pharmaceuticals. 3-
(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium brom-
ide (MTT) was obtained from Sigma (Shanghai, China).
Phospho-anti-Akt and phospho-anti-ERK1/2 antibodies
were purchased from Cell signaling (Beverly, CA, USA).
Anti-E-cadherin, N-cadherin, vimentin, and snail were
bought from Abcam (Cambridge, TX, USA). Anti-β-actin,
PCNA, Ki67, MMP-2 and MMP-9 antibodies were ob-
tained from Santa Cruz (Dallas, TX, USA). Enzyme-linked
immunosorbent assay (ELISA) kits for E-cadherin, N-
cadherin, MMP-2 and MMP-9 were purchased from RD
(Minneapolis, MN, USA) and kits for vimentin and snail
were from Bioss (Beijing, China).
Cell culture
HCC cell lines, HepG2 and SMMC7721, were from the
American Type Culture Collection (ATCC) (Manassas,
VA, USA). HCC cells were cultured in high-glucose
Dulbecco’s modified Eagle medium (DMEM) supplement
with 10 % heat-inactivated fetal bovine serum (FBS), 100
U/ml penicillin and 100 μg/ml streptomycin (Life Tech-
nologies, Cergy Pontoise, France) at 37 °C in a humidified
incubator with 5 % CO2.
Heat treatment
Insufficient RFA was simulated in vitro as described be-
fore [11]. Briefly, HCC cells were seeded into the 6-well
plates (5 × 104 cells/well). After 24 h, the plates were
sealed and submerged in a water bath set to 37 or 47 °C
for 5 min. Thereafter, cells were allowed to recover, and
when the surviving populations reached 80 % conflu-
ence, cells were propagated into the 6-well plates and
exposed to above heat treatment for 10 min. Then the
process was repeated and cells were sequentially exposed
to above heat treatment for 15, 20 and 25 min. Cells
surviving from the treatment of 47 °C for 25 min were
designated as HepG2-H and SMMC7721-H cells.
MTT assay
Cell viability was analyzed using the MTT assay. Briefly,
HCC cells were cultured in 96-well plates at a concen-
tration of 3 × 103/well, incubated for 24 h, and treated
with sorafenib. After 24, 48, or 72 h treatment, MTT
solution was added to each well at a final concentration
of 0.5 mg/ml and the cells were incubated for 4 h. At
the end of incubation, formazan crystals resulting from
MTT reduction were dissolved by addition of 150 μl
dimethyl sulfoxide per well. The absorbance was mea-
sured at 570 nm using an automated ELISA plate reader.
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Colony formation assay
HCC cells (1 × 103 /well) were seeded into 6-well dishes
and allowed to grow for 24 h. The cells were then incu-
bated in the presence or absence of sorafenib for
2 weeks in complete medium. The colonies obtained
were washed with PBS and fixed in 4 % paraformalde-
hyde for 20 min at room temperature and then stained
with crystal violet. The colonies were photographed
under an inverted fluorescence microscope (Olympus
IX51) equipped with an Olympus Qcolor 3 digital cam-
era (Olympus). The colonies were counted from 6 ran-
dom fields at 12.5 × magnification.
Migration and invasion assays
Quantitative cell migration assays were performed using
a modified Boyden chamber (Costar-Corning, New York,
USA) with 8.0-μm pore polycarbonate filter inserts in
24-well plates as described previously. Briefly, the lower
chamber was filled with DMEM with 10 % FBS, and
HCC cells (5 × 104 cells/well) in serum-free medium
were added into the upper chamber. After 30 min, soraf-
enib was added to the upper chamber. The cells were
allowed to migrate for 24 h at 37 °C. The non-migrated
cells were removed from the upper surface of the
membrane by scraping with a cotton swab, and the
migrating cells were fixed with methanol, stained with
crystal violet (Beyotime, Nantong, China) and photo-
graphed under an inverted fluorescence microscope
(Olympus IX51) equipped with an Olympus Qcolor 3
digital camera (Olympus). Migration was assessed by
counting the number of stained cells from 10 random
fields at 200× magnification. Cell invasion assay was per-
formed similarly, except that transwell inserts were
matrigel-coated.
Western blot analysis
HCC cells were lysed with lysis buffer [150 mM NaCl,
50 mM Tris-HCl (pH 8.0), 0.1 % SDS, 1 % Triton X-
100] containing protease and phosphatase inhibitor. Cell
lysate protein content was determined using a Bicincho-
ninic acid (BCA) protein assay kit. Equivalent amounts
of whole cell extracts were subjected to SDS-PAGE gel
and transferred to nitrocellulose membranes. The mem-
branes were blocked with 5 % non-fat milk for 2 h and
then incubated with respective primary antibody over-
night at 4 °C followed by the incubation with the appro-
priate HRP-conjugated secondary antibody for 1.5 h at
room temperature. Blots were visualized with an ECL
detection kit (Pierce, USA) and analyzed using Quantity
One 1-D Analysis Software (Bio-Rad, Hercules, USA).
Enzyme-linked immunosorbent assay
Cytokines secreted into the conditioned medium were
quantified using ELISA kits according to the manufacturer’s
instructions. The concentration of cytokines was nor-
malized to the total cellular protein using a BCA pro-
tein assay kit.
Xenografts assay
BALB/C nude mice (male, 4–5 weeks old) were obtained
from Vital River (Beijing, China). Mice were maintained
under pathogen-free conditions and housed in barrier
facilities on a 12-h light/dark cycle, with food and water
ad libitum. HepG2 and HepG2-H cells (5 × 106) were
suspended in 200 μl serum-free DMEM and matrigel
(1:1) and then injected subcutaneously into the upper
right flank region of 20 nude mice. After 1 w, mice were
treated with sorafenib by oral route (30 mg/kg/day), or
polyoxyethylenated castor oil as control every day for up
to the 22th day (n = 5 each group). Tumor size was mea-
sured with a caliper rule every other day. The tumor
volume was calculated as follows: TV (mm3) = (L ×W2)/
2, where L was the longest and W the shortest radius of
the tumor in millimeters. At the end of the experiments,
mice were euthanized by cervical dislocation, blood sam-
ples were collected via cardiac puncture after the mice
were anesthetized i.p. with 400 mg/kg chloral hydrate
(SCRC, Shanghai, China), and tumor tissues were re-
moved for fixation in the 4 % paraformaldehyde for histo-
logic examination and immunohistochemical staining.
Immunohistochemical analysis
Tissues were fixed in 4 % paraformaldehyde and subse-
quently embedded in paraffin. Paraffin-embedded tissue
sections were cut into standard 6 μm sections, deparaffi-
naged in xylene and rehydrated through graded alcohol so-
lutions. Antigen retrieval was performed 10 min at 92 °C
in EDTA (10 mM, pH 8.0) in a water bath. Endogenous
peroxidases were inactivated by immersing the sections in
0.3 % hydrogen peroxide for 12 min. The sections were
blocked with 5 % goat serum for 60 min at 37 °C. The
slides were incubated with primary antibodies for over-
night at 4 °C. Next, the slides were treated with appropriate
HRP-conjugated secondary antibody for 40 min at 37 °C
and then developed with 3,3’-diaminobenzidine. Finally,
the slides were counterstained with hematoxylin and
mounted. The slides were examined with Nikon Eclipse Ti
microscope under a 200× objective.
Statistical analysis
All values are expressed as the mean ± SEM. The
data were analyzed using the ANOVA test. A P value
of <0.05 was considered statistically significant. GraphPad
Prism (GraphPad Software Inc., San Diego, California,
USA) was used for these analyses.
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Results
Sorafenib inhibited the enhanced viability of HCC cells
after insufficient RFA
First of all, HepG2 or SMMC7721 cells were treated
with heat treatment for 5, 10, 15, 20 and 25 min
gradually as described above. Cells surviving from the
treatment of 47 °C for 25 min were designated as
HepG2-H and SMMC7721-H cells when we could see
the morphological changes. To evaluate the effects of
sorafenib on HCC cells, all cells were treated with so-
rafenib for 24, 48 or 72 h at different concentrations.
HepG2-H cells exhibited higher viability rate com-
pared with HepG2 cells at 48 and 72 h (Fig. 1a). So-
rafenib inhibited the viability rate of HepG2 and
HepG2-H cells in a time- and dose- dependent man-
ner (Fig. 1a). After the treatment of sorafenib (5 and
10 μM) for 24 and 48 h and sorafenib (2, 5 and
10 μM) for 72 h, the distinction of viability rate be-
tween HepG2 and HepG2-H cells faded (Fig. 1a). To
determine the long term growth ability, sorafenib was
allowed to treated HCC cells for 2 weeks. HepG2-H
cells had a higher number of colonies in comparison
with HepG2 cells (Fig. 1b and c). Sorafenib also sup-
pressed the colony formation of HepG2 and HepG2-
H cells in a dose-dependent manner. Similar results
were also found in SMMC7721 and SMMC7721-H
cells (Additional file 2: Figure S1).
Sorafenib inhibited the enhanced migration and invasion
abilities of HCC cells after insufficient RFA
HepG2-H cells displayed enhanced migration and inva-
sion abilities compared with HepG2 cells (Fig. 2). Sorafe-
nib inhibited the migration and invasion abilities of
HepG2 and HepG2-H cells (Fig. 2). Sorafenib (5 and
10 μM) eliminated the difference of migration ability be-
tween HepG2 and HepG2-H cells, and sorafenib (2, 5
and 10 μM) eliminated the difference of invasion ability
between HepG2 and HepG2-H cells (Fig. 2). Similar re-
sults were also in SMMC7721 and SMMC7721-H cells
(Additional file 2: Figure S2).
Sorafenib suppressed the EMT of HCC cells after
insufficient RFA
HepG2-H and SMMC7721-H displayed a spindle shape
with less cell-cell adhesion and increased formation of
pseudopodia, and sorafenib inhibited the morphological
changes above (Fig. 3a). To evaluate whether EMT had
occurred in HepG2-H and SMMC7721-H cells, EMT
markers were examined. Western blot and ELISA assay
showed that significant reduction in E-cadherin expres-
sion and up-regulation of N-cadherin, vimentin, snail,
MMP-2 and MMP-9 were found in HepG2-H (Figs. 3b
and 4) and SMMC7721-H cells (Fig. 3b and Additional
file 2: Figure S3). Sorafenib increased the expression of
E-cadherin, and decreased the expression of N-cadherin,
Fig. 1 Sorafenib inhibited the enhanced viability of HCC cells after insufficient RFA. HepG2 cells were treated with insufficient RFA (47 °C 5 min,
10 min, 15 min, 20 min and 25 min) gradually. Residual HepG2 (named as HepG2-H) cells surviving from the treatment of 47 °C for 25 min were
collected and used for the next experiments. (a) The effect of sorafenib on viability rate of HepG2 and HepG2-H cells was evaluated by MTT assay.
Error bars represent the SEM of data obtained in five independent experiments. (b and c) Colony formation abilities of HepG2 and HepG2-H cells
after the treatment of sorafenib were assessed. Representive images of the colonies were shown (12.5×) Error bars represent the SEM of data
obtained in three independent experiments. P value <0.05 was considered statistically significant; **p < 0.01, ***p < 0.001
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vimentin, snail, MMP-2 and MMP-9 in HCC cells in a
dose-dependent manner (Figs. 3b, 4 and Additional file
2: Figure S3). To explore the signaling mechanisms in-
volved in the sorafenib on EMT of HCC cells after insuf-
ficient RFA, we tested Akt and ERK1/2 signaling
pathways. HepG2-H and SMMC7721-H cells showed
significantly increased expression of p-Akt and p-ERK1/
2 compared with HepG2 and SMMC7721 cells respect-
ively (Figs. 3c, 4a and Additional file 2: Figure S3A). Fur-
thermore, sorafenib inhibited the expression of p-Akt
and p-ERK1/2 in HCC cells in a dose-dependent manner
(Figs. 3c, 4a and Additional file 2: Figure S3A).
Insufficient RFA enhanced the growth of HCC cells in vivo,
and sorafenib blocked the process
HepG2-H cells showed increased tumor volume com-
pared with HepG2 cells (Fig. 5a and b). Sorafenib sup-
pressed the growth of HepG2 and HepG2-H cells
(Fig. 5a and b). Sorafenib diminished the difference of
tumor growth between HepG2 and HepG2-H cells
(Fig. 5a and b). Significant increases of cell proliferation
were observed in HepG2-H cells, and sorafenib inhibited
the process (Fig. 5c). In addition, HepG2-H tumors
showed decreased expression of E-cadherin and in-
creased expression of N-cadherin, MMP-2 and MMP-9
compared with HepG2 tumors (Fig. 5c). And sorafenib
increased the expression of E-cadherin, and decreased the
expression of N-cadherin, MMP-2 and MMP-9 in HepG2
and HepG2-H tumors (Fig. 5c). However, there were no
apparent changes in liver, heart, kidney, lung and body
weight in the mice (Additional file 2: Figure S4).
Discussion
Local recurrences of HCC can progress rapidly after
RFA, and EMT may involve in the progress. In the
present study, we established a model simulating the
HCC cells after insufficient RFA. And, we showed that
sorafenib significantly suppressed the EMT of HCC after
insufficient RFA in vitro and vivo. The finding may have
a beneficial impact on the clinical practice of HCC ther-
apy and especially on the radical intervention used for
early-stage patients. Sorafenib may be applied to patients
who have undergone RFA, and used to improve the
prognosis via the effective inhibition of EMT.
Our previous study demonstrated that EMT occurred
in SMMC7721 and Huh7 cells after insufficient RFA
[11]. In this study, HepG2 cells were treated with insuffi-
cient RFA gradually as previous, and EMT also occurred.
In another research, HepG2, Huh7 and HepG3B cells
were exposed to 50 °C for 10 min, and EMT occurred
on day 5 after treatment, which was partly consistent
with our results [12]. Our results further confirmed that
insufficient RFA promoted the EMT of HCC cells. Fur-
thermore, in our results, sorafenib suppressed the EMT
of HCC cells after insufficient RFA, which was not ever
reported before.
Fig. 2 Sorafenib inhibited the enhanced migration and invasion abilities of HCC cells after insufficient RFA. The effects of sorafenib on migration
(a) and invasion (b) of HepG2 and HepG2-H cells were shown. Error bars represent the SEM of data obtained in three independent experiments.
P value <0.05 was considered statistically significant; **p < 0.01, ***p < 0.001
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Recently, Akt and ERK signaling pathways have been
reported to play an important role in EMT in HCC.
MicroRNA-331-3p promoted proliferation and EMT-
mediated metastasis of HCC via the suppression of
PHLPP-mediated de-phosphorylation of Akt [20].
Maelstrom promoted HCC metastasis by inducing EMT
by way of Akt/GSK-3β pathways [21]. MicroRNA-21
suppressed PTEN and hSulf-1 expression and promoted
HCC progression through Akt/ERK pathways [22]. Akt
and ERK pathways were also mediated the EMT of HCC
cells after insufficient RFA [11], and sublethal heat treat-
ment promoted EMT of HCC via ERK pathways [12].
Therefore, the inhibitors of Akt and ERK may be applied
to suppress the EMT of HCC cells after insufficient
RFA. However, all specific inhibitors of Akt are in pre-
clinical trials [23, 24]. Sorafenib was originally developed
based on its inhibitory effect of Raf and receptor tyro-
sine kinase signaling, which further inhibited the Raf-
MEK-ERK signaling pathway [25]. Sorafenib has been re-
ported to suppress the growth and metastasis of HCC
via Akt and ERK pathways [26–28], and inhibit EMT of
HCC induced by growth factors [14, 15]. In the present
study, sorafenib inhibited the up-regulation of p-Akt and
p-ERK1/2 in HCC cells after insufficient RFA, and fur-
ther down-regulated the increased expression of N-
cadherin, vimentin and snail, which resulted in enhanced
abilities of migration and invasion in HCC cells after in-
sufficient RFA.
Recently, sorafenib has been used to strengthen the
curative effect of RFA in HCC. Fukuda H et al. reported
that combination of sorafenib and RFA may be superior
to standard RFA alone in the treatment of HCC tumors
Fig. 3 Sorafenib suppressed the EMT of HCC cells after insufficient RFA. Sorafenib was used to treat HCC cells, the morphological changes of
HepG2 and SMMC7721 after insufficient RFA were displayed (a) and western blot was used to determine the expression of MMP-2, MMP-9,
E-cadherin, N-cadherin, vimentin, snail (b), p-Akt, Akt, p-ERK1/2 and ERK1/2 (c)
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smaller than 3 cm in diameter [29]. Li Y et al. reported
that the combination of sorafenib, transarterial che-
moemboliztion and RFA proved both safe and effective
in the treatment for unresectable HCC patients [30]. An-
other research demonstrated that sorafenib suppressed
the rapid progress of HCC after insufficient ablation
therapy in an experiment in vivo, which seemed like our
research [31]. In their study, sorafenib was able to inhibit
the up-regulated expression of HIF-1α and VEGFA in a
xenograft model after partial RFA. However, rapid pro-
gress of HCC after insufficient RFA was not observed,
and further mechanisms involved in the progress were
not investigated. According to the guidelines of the
National Centre for the Replacement, Refinement and
Reduction of Animals in Research (London, UK), in the
animal experiment, we produced reasonable evidence to
support our findings in vitro by stopping large studies
which would result in a large augment in animal use. In
our study, sorafenib inhibited the migration and invasion
of HCC cells through the suppression of EMT after insuf-
ficient RFA in the simulated model. Furthermore, in the
mice model, HCC cells after insufficient RFA exhibited
larger tumor volume compared with HCC cells after con-
trol treatment, and sorafenib inhibited the growth of HCC
cells and eliminated the difference of growth in HepG2-H
and HepG2 cells. So sorafenib may be used to prevent the
progression of HCC cells after insufficient RFA.
Sorafenib causes multiple human toxicities, including
use-limiting anorexia, GI bleeds and hand-foot syndrome,
which may lead to drug discontinuation or dose reduction
that can decrease the potential life-prolonging benefits of
sorafenib [32, 33]. In our research, sorafenib (5 μM) sig-
nificantly suppressed the enhanced abilities of migration
and invasion of HCC cells associated with EMT after in-
sufficient RFA in vitro, and sorafenib (30 mg/kg/day)
inhibited the growth of HCC cells after insufficient RFA in
vivo without more toxicity for mice. However, in the
present study, we just used the simulated model which
Fig. 4 Sorafenib suppressed the EMT of HCC cells after insufficient RFA. Gray analysis of all bands was used to quantify expression levels of MMP-2,
MMP-9, E-cadherin, N-cadherin, vimentin, snail, p-Akt, Akt, p-ERK1/2 and ERK1/2 in HepG2 and HepG2-H cells (a) The concentration of cytokines
secreted into the conditioned medium of HepG2 and HepG2-H cells was detected by ELISA analysis (b). Error bars represent the SEM of data obtained
in three independent experiments. P value <0.05 was considered statistically significant; **p < 0.01, ***p < 0.001
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may not be representative of the progression of residual
HCC tumor after insufficient RFA effectively and only
provided the preliminary basis for the application of soraf-
enib to prevent the progression of HCC cells after RFA,
and more mechanisms involved in the progression and
clinical trials should be investigated in the future.
Conclusions
All in all, the study focused on a simulated model to
understand the recurrence of aggressive HCC after in-
sufficient RFA. This study demonstrated that insufficient
RFA promoted the EMT of HCC cells. Sorafenib
inhibited the EMT of HCC cells after insufficient
Fig. 5 Insufficient RFA enhanced the growth of HCC cells in vivo, and sorafenib blocked the process. HepG2 and HepG2-H cells were injected
subcutaneously into the upper right flank region of nude mice, treated with or without sorafenib, and tumor volume was measured. (a) Tumor
volume was measured with a caliper rule every other day. Data were presented as the mean tumor volumes of mice. (b) Tumor size of the 29th
day was displayed. (c) Tumor sections were stained for PCNA, Ki67, MMP-2, MMP-9, E-cadherin and N-cadherin. Representive images of
the immunohistochemistry assay were shown (200×)
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RFA, and may be used to prevent the progression of
HCC after RFA.
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